IMVT - Earnings call 4 2021 | Immunovant, Inc.

Due to licensing restrictions, you must log in to view earnings call transcripts.

Operator

Good morning. My name is Daryl, and I will serve as your conference call operator.

[Operator Instructions] As a reminder, this call is being recorded.

Joining me on the call today will be Dr. Pete Salzmann, Chief Executive Officer of Immunovant.

Reform would include remind the certain the Securities I conference that meaning begin, Private will XXXX. call forward-looking Litigation we like everyone to today's of Before of Act statements within readouts forward-looking future trial, safety Immunovant's the including of and timing, the include, potential expectations results indications. and data and of example, regarding timing product statements These the and statements of of efficacy design Immunovant candidate the announcement regarding for its future clinical

guarantees of various indicated not to performance and uncertainties, These known to are forward-looking from which or results future are subject the risk assumptions, those statements vary materially actual and events anticipated. could or unknown, cause

the For encouraged recent review more report most investors X, Immunovant's to are XXXX. on SEC June filed on information, with quarterly Form XX-K

would Salzmann. the to call Now to turn Salzmann. over Thank Dr. I Dr. like you, Pete

begin. may You

Peter Salzmann

joining this and to everyone I everyone, that you review thank safe purposes forward-looking harbor provisions. corporate of morning, appreciate update a call Good on Immunovant. presentation for statements for for today's the conference advising contains Daryl me

this In of aware, a that by intends to shares outstanding make you be acquire our of its to Roivant, to the in us may already it to stockholder, March company, the state not proposal as XXD Roivant. XX% addition, amended year, owned

advisor. or Wachtell, to legal as Roivant response financial adviser prepared from to its Board filing, & special negotiate Lipton, retained parties. of directors, such Centerview our Rosen Katz of committee to has proposal independent be as the committee evaluate In Directors The and formed its consisting Partners a any special and other

now to our Moving update. corporate

shared levels voluntarily the elevated February in of dosing for clinical in time, XXXX. treated As a you and quarter forward future. in wide for with LDL patients findings. IMVT-XXXX review our our we that our that to sharing insights paused At due come share in doing year, we trials to this we that to look observed recall, we this would excitement were and our program back We

months. last the We learned of lot over couple a

First, what patient end agent about suffice XXXX say these do. IgG return needs of the patient we've that the at refined presentation. to and anti-FcRn to needs. nicely I'm ideal to But lowering view going across of learned to insights should of patient very the a doses more our observed strong matches important an range

learned XXXX's we've profile. about a lot Second,

I In covering addition we wider will share to of believe our window LDL than that manageable, XXXX the why anticipated. impact therapeutic is is also we

seeing have early disease activity Third, we've returning states. clinical pressured clinic forward different to next this later the and development year. year finally, or we're to biological we're across now looking X to have patients And to excited met in various options,

start Let's about XXXX. we've what reviewing by learned

share. findings X In important fact, we have to really

thought doses is the we're First, we at than more has studying, a potent window. and broader therapeutic XXXX

Second, changes leads and individual linked all for in IgG, albumin patients. this tightly to and LDL are predictability

Third, And a there in LDL for in and favorable LDL. changes trade-off changes albumin and appear IgG several important manageable in desired changes fourth, between undesired the is reasons.

one-by-one. concepts these take now me Let

reduced is we dosing. while weekly dose, to X a and weekly reductions understand previously observed weeks. XX milligrams substantially when high of XXX XXX weeks We deeper weeks milligrams IgG for that weekly milligrams X XXX IgG at very and with milligrams now also a dosed potency, observed during high the Regarding XXX over dose to in weekly milligrams had we compared reductions XX XXX

dose. thought. broader therapeutic baseline, noted baseline than LDL other words, changes change now in in of XX XXX-milligram I've for LDL XX% for GO-X. baseline change LDL compared dose ASCEND from XXX-milligram we in window have increase that we and from data is the learned the In XX% at XXXX to to that weeks the all also the the The compared a we

we thyroid serum with our correlated levels albumin predictability, And changes. study the in LDL were with learned not correlated Regarding hormone highly were data. changes that

via Of Fc both correlated represent The that course, effect we mediated as already tightly therefore, of on-target effect. understood and target appear very that IgG was an receptor. albumin and highly new were learning albumin the on lipid also, changes are reductions changes elevations an with to correlated

albumin Based external lack levels synthesis albumin consensus of on stimulates observed plus in VLDL. expert albumin lower thyroid and the consultants the an between hormone the is observed of LDL, LDL, correlation between and of that correlation serum hepatic

correlations important treatment, observed another off we also baseline LDL treatment, characteristic. both to addition In which observed to the predictability returned is during that albumin and

GO-X, in ASCEND-WAIHA magnitude ASCEND numbers. believe in the These LDL Outside on based changes serum we ASCEND of stored Nevertheless, ] were indications. dose-dependent small in a appeared injection we healthy site subject MG differ and of observations will similar observed with across and the in analyses not pattern of [ quite consistent a the study impact

and increases the the in tested IgG in doses after X milligrams of ASCEND did or Whereas and near across reduction patients doses reduction reduction, XX remained not clustered therefore, between of reduction, normal for limits on peak albumin albumin XXX the reduction all reduction weeks of doses about demonstrated half IgG the data LDL XXXX's favorable cluster. The dosing. the IgG New albumin trade-off in X for the GO-X. a range

dose larger as the albumin subjects. -- resulted these results LDL small patients reduction mild The dose between shown in previous can XXX-milligram for the in mild. from in slide. These the this on reductions see prior dose albumin XX dose the were a in the XXX-milligram Consequently, the changes reduction increases the in on reductions over on for and in week XXX you larger albumin As in widespread XXX-milligram graph, albumin period.

for that dose in the the stage the provide indications. One and the physicians is approval have have So and LDL We've patients good ways manage we should managing for indication trials assuming about we down learned increases? learned lever solutions what clinical LDL in that this road, multiple for and treatment. to key future of customizing different

may initial very treatment or induction, weekly. an milligrams indications begin dose or For given high a milligrams dose with require XXX high XXXX, XXX of that high

maximize that long-term dose efficacy in while we patients. extension, small weekly, weeks. the excursions is be monitored. during be where LDL during or LDL milligrams spectrum, the albumin and be a standard over and the with XXX to Depending changes maintenance dose will the goal at phase factors, weekly At be on median minimizing maintenance the might to At most increase at was of therapy short-term of milligrams disease severity likely Recall a is other the for simply XX% XX might the end XXX anti-lipid LDL induction other XXX of managed anticipate immunosuppression. that

How physicians physician expect middle and estimated both were achieving was and most then is LDL in such an designed presented to and anti-FcRn handle suppression response increases or envisioned and who hypothetical the higher we to experience changes practice. than patients the with chronic for for in with LDL are XX%, of prescribing increase that LDL many either to product milligrams XXX-milligram will an no weekly. XX% we IgG spot product of of see modest their spectrum, of Physicians profiles a on In for LDL share market doses or XXX- XXX a impact impact patients. a patients with in test sweet LDL? research albumin This

We disease of lines different are severity of and across therapy. across able to test range their prescribing a projections

not change anti-FcRn an neurologists prescribe to showed XX%, medication research market increase in LDL for of really in willing did myasthenia This an gravis.

XX%. group neurologists an or with this LDL using example, XX% anti-FcRn of without about an of For their signal for of practicing anticipated medication MG patients

in of therapy, lines change for early little LDL change slight in there but increase very For share, projected an of decrease was an increase and of very share XX% market for market generally LDL suggesting a a XX%. little

this they market therapy. such the would control would increased less statin to or that of or hypothetical that patients share might anti-lipid of and anti-FcRn be with chronic readily a physicians setting, changes anti-lipid LDL a did be by LDL profile these And other note fact, other When these a addressed easy presented XX%. magnitude an product that with believed anticipated product of In some in fall believe therapy. the statin by they that for

patients who are Similar trial post slide in already This in to research with patients trials happen who We other increases ASCEND the and for range. LDL with a a statin be taking of XX% of patients MG next also physicians on statin. analysis X yielded GO-X X comfort a obtained. whom identified hoc in enter is a and specialties could trial our ASCEND baseline and being X LDL the

the these elevated. patients X X of randomized small varying taking and low X to active randomized X additional LDL, patients. treatment GO-X, were were LDL to placebo. were In statin then during XXXX were taking to levels treatment quite patients arms with for had moderately a All for statin patients changes a patients from to randomized ranging ASCEND XXXX.

statin ASCEND to In right-hand a taking the side of treatment on and randomized taking was the MG. MG and to were X a were X placebo patient while randomized an arm, ASCEND in statin graph, active patients

With XXX decreased more than to actually milligrams, XX%. was LDL the patient who randomized

On randomized milligrams patient the other hand, XX%. and to by LDL XXX placebo, the for patient the to randomized increased about

that all of MG randomized should LDL stored the at show hoc yellow the the post MG note patients, of samples the based I for All bars of end on serum. all eye The of analysis, same where value are their the a represent disease observations open-label at the end treatment treatment. to bars extension. and relate of don't of LDL period during yellow the thyroid true patients the the is

happened is will a likely and find that these this a patients views sample statin, be very data work just of to in to small who with encouraging we Although situation. states also experts' consistent on this be

anemia. warm now Turning to hemolytic autoimmune

are We by acknowledging are data findings also while limited. very early encouraged the

hemolytic the therapy. hemolytic anemia an with As not study with patients tapered, for line recurs to of trial often are steroids These in often are patients is of treatment failed open-label autoimmune so the these When have a treated other warm reminder, steroids disease disease gain prescribed, ASCEND-WAIHA are who very dose a prior are anemia. FDA-approved high the warm immunosuppressants control. autoimmune and

the X other -- dosing. or is by XX for their X a pause, weeks a And considered XX rule. weeks endpoint had ASCEND-WAIHA. patients dosed improve of study. is or randomized like X we on dosing. X does Patients don't grams completed don't who Prior X as only spontaneously patient in and patients that patients completed primary general responder. of the the X therapy this deciliter improve per A hemoglobin

voluntary One of program due dosing paused the patients pause. these to wide

event duration WAIHA. study adverse for a patient from history a was and of in the a short ITP other The serious of recurrent both ITP through with patient

deciliter, per the response the to was prior and program weeks this of hemoglobin X patient shown in In treatment. completed who and an a the terms had pause, on completed line patients here well to increase over therapy therapy, weeks grams open-label of during XX increase strong maintained XX XX with

bilirubin and also hemoglobin the particularly expert this in X a another on modest of one short patient biomarker prior improvement the ASCEND-WAIHA not steroids discussions, improvement trial. of Based There response immunosuppressives is did and term, of bilirubin that for during total entry subject. other had XX in Note potent therapy. who in important and WAIHA, therapy matched in patient into rounds this had failed X was total who weeks respond weeks to patients after the the XX

to wide of eye As difficult, Prematurely IIb And study unanticipated efficacy study you a at XX. severe investigators. a always subjects the discontinuing especially XX% and anticipated. in we program in our the And so thyroid patients only XX review. bit case, projected randomized, Phase primary due terminate XX those of to moderate evaluation to disease for had of our prematurely more know, is to as week XXXX over be this completed lipid

a assessed the visit, of was dependent total that any compared dose achieved decreases each in that size in study group. to XXXX difference reviewing a from a whether observed a with it a On proptosis the is patients the no rates XXX-milligram clinical that stimulating were perspective, IgG the dose, thyroid proptosis our risk to minimal used dose answered the and dose calculations visits, designed study appeared in this data certainty. risk with proptosis, that What response did at XXX-milligram with question the XXXX observe of for power study and immunoglobulins. From difference when approximately for early enrolled placebo the this improves with XX-week we answer, the XX% be XX% possibly course could XXX-milligram Consequently, response cannot to responder be is assumed placebo. manner,

would the Due X have to dose and group persisted subjects design, XXX-milligram to be observed these ] for of simply the XXX-milligram had groups meaningful and determined. the comment. is rates trial cannot [ in unbalanced assessed to were response gone randomized XXX-milligram if Whether allow these any unknown completion in the

trends or magnitude. the lesser Efficacy prospectively defined secondary endpoints in

a responder in the clinical not example, for evident, . activity were For improvement for example, rate

important is study rate responder was only endpoints. proptosis remember primary it the However, to the secondary the sized for that and of assessment not

to We believe evaluated appears of observed XXXX coupled the be regulatory we forward We're at of we that when prudential to thyroid that by with and efficacy the continuing the of this continued declines results in total the enrolled leaders. in discuss these to discussing second believe in efficacy in immunoglobulins data indication warranted. subjects are visits with XXXX may trends where key discontinuation year. opinion the Despite suggest study, maybe TED the agencies most our the much of induced designs disease premature very review, We're IgG disappointment were investigation with the looking early parameters, encouraged anti-FcRn and another trial our to this work. stimulating half

a the autoimmune So and XXXX trial FDA Phase of plan initiate a indications, next? TED next MG indications in to agreement, we trial initiate late as clinical X XXXX, a these as in early XX do we [indiscernible] over a in trial. anemia or clinic from the warm And return plan the time well believe pivotal we similar in to frame.Beyond to and what's resume here? and Where on trial go these be hemolytic initiate we could X studies II X new pivotal months,

Bill therapeutic track fits last Immunovant, weeks, development of that With And having excited already pleasure experience clinical of all been come past. Bill consolidated industry-leading great up areas, experience to him with as a in on he's Dr. medical Bill's to across we've working this of of including over leadership under lot Bill programs see the in well very brings mid we the are and including years multiple XX of our a very activity, pharmaceutical positive indications. in impressive late-stage breadth potential scientific early, with immunology, drug the Macias. and had of numerous and over IMVT-XXXX development. record I've speed to it's fun impact. the a experience

$XXX.X of we plans expectations note XX, have million, to Finally, calendar reviewed, to cash year these March on balance and I just want to XXXX. XXXX, our based that and enough as timing related our existing into programs, get capital current of the as of development our us second half

want insights Before is to with diseases. our people I opening to the At high normalized unchanged, gained. patient line the bar autoimmune remains return to we questions, from Immunovant, the This physicians needs. need really what to to and tools important. most with keeps is on focused what and understand on people what guides us us autoimmune diseases It will living those require deliver vision

with need? depends. an The answer and scientific patients to much almost advocacy how it Our suppression recent the driven yielded discussions autoantibody thought certainly, critical is groups leaders, experts question one to IgG insight with condition

patients new suppression. lot acute with with need a onset of flaring disease and disease, IgG Patients conditions patients with generally

very doses quickly when fact, many prescribing gain in these In physicians with steroids control. situations, high to disease start

best also condition On achieving hand, control. They the and come activity maintaining agree Experts under least than patients therapy suppression. initial other is the less control, long-term control disease IgG efficacy disease immunosuppression. need chronic target the agree easier these is his disease will should that has likely whose that with

lowering. high-dose case, begins Myasthenic are high crisis, the IVIG. condition doses rapid of begins following examples doses, therapy and organ the clinical in with deep immunosuppression and where anemia high of hemolytic care often is and another rejection this warm autoimmune solid IgG CIDP where acute standard with transplantation

gravis other cycle, phase the of doses treatment symptom of tapering longer On or benefit. immunosuppression lower In been induction. dose clinical warm physicians maintaining the hand, goal this while to are or then myasthenia begin minimize intervals generalized autoimmune treatment usually time, to and effective a with CIDP immunosuppression without patients of order high for maintaining dose crisis, symptom striving in doesn't control the and for In treatment for some between control. switches a achieved and case has the anemia hemolytic

During ] may a simple easy to apply on patients auto their many antibiotic-driven higher also phase subcutaneous the development be believe conditions. such specifically, for insights, we believe device -- to even delivery And [ the injection. convenient of important a These class-leading an implications the range provide as suppression with of subcutaneous which which ability we premium anti-FcRn, delivery maintenance treatment, an to a mechanism wide IgG key. of will a administer place

I'll for thank ask the With open the that, questions. and want you for to your attention, to line I operator

Operator

first Truist. the line from Instructions] Our with come questions Karnauskas of [Operator Robyn

Robyn Karnauskas

to saying I'm where you because uptake sort of proptosis like sort an what the to even a dose will trying full therapy it's shown for Great. likely from you that don't even that -- drug? at we've though end of with be that that have high the like -- be all likely very doctors? understand I'm this challenging TED data acute so more the data you what So to may the will and trying you've are your though is for comments done most mean injection

high the see the achieved at you higher trying It maybe start. need doses to see dose, reduction -- so I'll you sounds going you're said to what proptosis with that like may something end. to understand I'm level maybe achieved

that do that if work that's indications dose what forward? that think dose modeling? are that for do do the the you now most doses? -- to likely the you take use you really what with like because have be think XXX, higher think So likely then that help likely most the will you you maybe indications And for less be we like then the TED lower And me amount, understand, -- where should will

dosing? lower what a there. go it sustained so cholesterol lower you're the and dosing, comes question you seeing had with that frequent, you of less decrease? then is couple maintaining And less was even other of I IgG or less of sort about what des? Could fully see is like XXX frequent Argenx sort you frequent could don't in So doing back, you're questions

on that. how data all really about trying given the delve drug us of you've given just to today? out to I'm Sorry figure your sort

Peter Salzmann

Robyn. Thanks, Yes.

of always, a questions. As great set

the with patients simple, is concept start the have really, concept different is that which is the And one, needs which me let the IgG So different second end. quite at for suppression.

to IgG are going Some suppression. need deep

to going now need are a range XXXX of Some both. deliver suppression. strong that we've shown IgG And doses across can

mentioned or high So I in short period conditions that. can who unmet LDL over the XXX milligrams dose deep case. could need a patients for where And is a there of changes high that higher albumin then reduction, a very or milligrams time and XXX XXXX, important. less a doses those are need, IgG are few the or of be The provide very when

there's across of of in maybe degree bit On going during achieved symptoms belief in more maintenance the are experts that a needed to be hand, the that improvement disease acute they've who chronic the many range. suppression seeking to the will range going for or speaking a with XX% patients of there's be of instead remission And XX% that the phase other little be range in conditions, a phase. IgG less,

an data potentially in example, provide lower every learned and LDL. So sweet as reduction percent -- our you that in XXX spot with albumin is what week, XXX XX-ish changes IgG other mentioned, milligrams, this can we is from that minimal of as dose

seen a that So those across the the a chronic for profile indications, important the is of of patients. setting, concept both is at end wide which range acute competitive lot and that's really we've really in XXXX

-- because eye very inconclusive makes of disease, is was that efficacy study to I really of data the it the to challenging. close terms thyroid interpretation had what stopped reviewed completion, before In there the and anywhere is be

of the are short At which efficacy, transparent an the impact. and improvement we I fell to degree our of and the encouraged same between clinical in that want biomarkers very time, expectations. by bit apparent observed, We a the biomarkers correlation be

ideas we we trial regulators. efficacy a half studying a to that, on have optimize clinical that's thyroid II Phase trial and and based meaningful that year So and competitive, discussion we where were plan can and second who some deliver after in to really with eye a start of the experts for this disease

Robyn Karnauskas

on question the what of therapy do follow-up so population was what percentage like, the what eligible be II is be [indiscernible]? like That what my design And you of might to the the narrow might you -- me you sort would be of for for versus us percentage think that help your in population population after? Phase in that go might

Peter Salzmann

and spectrum, opportunities That's do ends see with on a of discussed and on. haven't little great something who've mean, of symptoms. both a I a question Yes. past, achieved in already, and I we've mild full already more actually, patients TEPEZZA working see had we're of bit remission as course patients who -- we disease have their the the

Operator

from come next our of line question Archila with Stifel. Derek is And the

Derek Archila

comprehensive Thanks for update. the

a just us. from So couple

you about patients on give doses? guess, can kind for your the you do Were on? talk dose were were statins you of dose to the can that the and were kind And given in you for on XXXX, indication? there? a receiving differentiation where statins some feel of I the max that they provided in then sense continue they statins? the data that mid us is your Or they on Just range MG of lower choice landscape competitive on

Peter Salzmann

are Those really good questions.

particular, August something in to important equally deep talked to rate. many competitiveness And myasthenia, think similar in and rate, indications other myasthenia will in that will that in addition we I I more is think be our by released even percentages may the or the responder in we be is driven tolerability. about results responder competitiveness efficacy, regard myasthenia, be to other back when safety in with the So

conclusively in enrollment also trial. too in is and who trial suggested XX-point think a I validate the into their in those clinical pretty patients logical X, deep have IgG nipocalimab link LDL, deeper MG to had improvement was MG link a between body X, during a X-point had Remember, that tremendously didn't your they Those small have reductions improvement patients just but a And and treatment life talked our different data. with of about LDL. than we in although the responses, was those

So Robyn the to the point about end at this is well, a this you that gets asked -- which sometimes need deep there reduction. concept because as me the

you, Sometimes need a strong reduction.

For patients the or significant. who the changes that a really the best discussed those we much maybe in move IgG be down are believe LDL levels the with into can looking have the patients and we we've their past, X,XXX, suppression. of of big clinical into maintenance Then, that reductions symptom to as change that achieve shot lesser a long-term many chronic patients less to as in taper achieving big, of deep in also setting, We move think control. given become deliver. then a as will IgG to albumin they extension phase, able do And we

symptoms. go become in they experience the then improvement magnitude. those chronic in the move events in So reasonable albumin front end a a LDL deep or And the away important into in in they and trade-off probably less either that their changes short-term as much for might are the adverse phase, clinical

weren't milligrams. XX weren't was doses, One atorvastatin on atorvastatin on atorvastatin milligrams, or of sort They like of X was either. the statins. were on of at None they them a on they midrange terms statins, X Crestor high low had the super were doses on were maybe X of but least patients In XX the there Several milligrams. XX. or but XX range were X statins, were person of

were LDLs the XXX Others at they somewhere the or less. to range. varied baseline. in -- mid- had XXX sort XXX, trial statin range XXX statins were So you therapy the at even more their even the saw the LDL into of with the And coming on

Operator

with of Guggenheim Suneja the come Our next questions Yatin from Partners. line

Yatin Suneja

before one, into more on do from other you lower couple Number establish do question to is you pivotal do have me. second then And work, study. even or move TED dose Just a have studies? the a to dosing the you

X that about patient past, that the hearing in excited the have really not level you we're that pretty were but of data excitement You had now same you XX patients. generated

us little more bit into a the sense give data? So TED

Peter Salzmann

are the of them in a the a we -- finding believe X that path. excellent really studies setting you Yatin, examine potentially II in we both actually. one, some that can that. on Phase first things glad biomarkers or additional the critical like We the we anti-lipid do correlate do dose where with context trial or on questions. I'm of where Because those may I asked population not are the in disease a could concomitant therapy Phase dose-finding

in that the we models and impact albumin had and to very, shown from models populations. albumin us are some nice now we LDL. tight are believe X past. really intervals different because maybe And to We've predictable. the in open-label much than reason and week computer the correlation every quite reduction show do is albumin different general But allows those having PK/PD and studies data we robust to and And a LDL. very not a And path XXXX and -- have we and well IgG anti-FcRn's different between PK/PD and for dosing of had on All and dosing as week of had extension recently. that other IgG healthy a trial, extent, every again, a clinic disease we in study probably MG range build in that more injection critical returning for in to completed site other the data our those, the doses

go terms parameters. those in range to design which that on that that trial confident test So difference a will their a of back have effect with meaningful of we allows the we'll to doses, feel us in agency

Yatin Suneja

And it. one just more... Got

Peter Salzmann

Go ahead, Yatin.

Yatin Suneja

transaction? are And in on One play out? price? Can might about majority process going then running you where question the have holder, other asset? is you a is are They parties can to talk that also engaging are decides you I proper the Okay. a they the who Who interested how more be Roivant force offer. maybe also the

Peter Salzmann

Right.

So question. for thanks that

independent M&A on in sort majority transaction following an there controlling. the how be on the I Really any their and M&A here to party. that any response any you're is governing directors parameters, or works. in charge webcast, that with in could if special Board proposal negotiate to And from As process committee which which the of evaluate put back that committee, of prepared with and slide, are Roivant Directors to up I've XXD, -- in important our transaction shareholder, that other Roivant's specific of consisting a particular, formed on that regulations the is first amended shared come and many special

that committee has advisor, engaged financial Rosen Katz legal a special as & Lipton, Partners And their as Wachtell, Centerview adviser.

place. is all machinery the So in

Given on the the really can't I situations. comment committee. tight of regulations else the special anything around these the activities about process of or types

And Yes. you TED, and asked answer about, I question that didn't yet.

an it's important think question. I

saw proptosis a time elements patients including points we from the where similar about absolutely were as we IIb the the this IIa X the at the what of trial that exciting open-label trial. of early order we to And very magnitude of in had are presented improvements well, in trial. So that data were excited we there that in

IIa of trial more all impact doesn't are IIb have treatment trial the on of their stages based and in definitive hoping don't complications trial as unexpectedly early of to there's the failed were a because it suggest people and this those it. IIa data trial the unblind when for this have than it do Nevertheless, that as stopped was data different we definitely and you the trial. of strong we unblinded, and have magnitude in We at a finishing data from

ensure significant makes future So and that that us is not really population can want right study really in statistically also to significant impact. any the we a commercially significant demonstrate but -- just impact, clinically where

Operator

if question mute James. next on could the Raymond Our check Danielle, Brill from with Danielle line of comes you're please? you

Danielle Brill

Can you about sorry [indiscernible] question. that? the me, hear

you first have with all clarify any haven't LDL magnitude then findings? the And reported thoughts wanted was, just competitor programs consistent to albumin if across as impacts to I why in that indications? impact fact, similar curious similar So of

you Pete, reporting healthy in line reduction then volunteers. milligrams. of Phase magnitude XXX-milligram with what I the presented XXX IgG here the believe I And different IgG for from with the you in the reduction slightly data you're looks was new data saw

Just dose many you is included were curious And patients the that site? in this confidence actually low data in how what you're what here seeing gives real?

Peter Salzmann

hoc Caveated to with dose slightly the of the was the the and So consistency magnitude by change indications, weren't the with serum. stored and all post we other they the regard reduction that across on run the are small they correlation when site fact degree, study, we're in healthy injection or indications in numbers analyses, albumin study, the and across consistent looked in those subject the were was which dealing indications. the prespecified, LDL findings that of with

cautiously. need view and serum But but to disease a run run eye is so that specified it's those have to we thyroid was the been prospectively. consistent it on serum when findings we with pretty slightly do on stored not standard as standard test, cholesterol patients, Cholesterol very the and ran stored cholesterol the

across So us that all sense those in things similar was to give really LDL magnitude change a indications. terms of in all triangulated the the

between that our that There's any in surprised correlation which and The were relationship other we we bolster didn't general. data, that a LDL. were levels hormone was not just between thyroid -- X well-described observing correlation. a thing little we those But find in that is

terms this change confident change. LDL of indications of consistency terms degree and in by LDL across the in albumin difference and of by pretty of degree dose So we're of impact

effects, slide In at with we've little up but a have extent bit curve, right before, I IgG just the IgG now, the bit the later consistent IgG with different are points. some I across to what different see in saw generally terms of albumin We which deeper at a consistent weeks. of the changes, XXX arm, weeks seen those XXX the that shows deeper the time arm, can which were the these and of that are think XXX the there's see you to also target get additional doses. and suppression and reduction both the you on being estimates give we little or with these magnitude XX being us for degree good curves, of that would XXX, little a confidence the both X that compared so after X of biomarkers, XXX

And we've as in also forward. helpful IgG to the the models frequencies. see dosage dose with estimate us might best we that That's taking simulation going computer I allow mentioned, or those building been reduction that different really dosages different

Operator

Leerink. from Smith Thomas the with come SVB of questions line next Our

Thomas Smith

for help market conduct some research Did presented. then any you're some And the multiple update. clinical agents early to you factors that feedback? Thanks the in FcRn these the going And if presence what to later you us about Appreciate of understand getting study of terms gating market you year? again marketplace? contemplate was is of just thinking of this research studies timing, in can so, outstanding the the how

Peter Salzmann

maybe more lot the kind ways theme physicians double choose a that was clicked LDL of the subcutaneous I'm that did having themes, that that And but I the disadvantage thought of on format change modest of in see most showing important in here. wasn't did I -- We big recognizing We market one interesting described. change picked different actually. modest LDL, that disadvantage Absolutely. do a a simple as was counteract what of that the research profiles. perceived of in injection can change as a you the we benefit

didn't with kind that. view they impact less didn't in was here showed start as about margin actually when on LDL. something address something data, of I We would the prescribing They XX% but really looking different at for there, than a significantly board they a and specialties did their at to neurologist we across and much that have that a patients ask statin. physicians, or work statin and may of the lot So similar have you changes but the pretty so you're of

XX% consider. they many So of factors that sort just when of you're one it's at rate, that

back think go to to points I and the on are to they'll the things within And myasthenia the deep I going the making efficacy real drivers. ability responders be they're like was and achieve that achieving

line getting different. bit the a is in time for myasthenia, back clinic, study to little of so terms each In

-- we the with January pause trial. we program other meeting Phase just myasthenia, a on prior pivotal very our very, MG II for gained FDA features for in based productive had with the a that, across the good of to back And on design and in the So alignment pause all voluntary the of many end FDA the trials.

forward be most actual We able believe to we're will trial pivotal that into the carry those of planning.

we're come cholesterol here experts with up as finishing straightforward. which So and to guidelines dosing that, like forward the with allow that computer modeling, pretty should develop will things our to then us and we're recommendation be monitoring

to do regard we to what that's So myasthenia. with need there

autoimmune trial is sort more open-label it to less disease that since by was totally didn't be trial, of an anemia to it have Warm eye hemolytic -- be it didn't thyroid terminated or paused, the trial. have

we're of the back one, monitoring roughly frame the forward just the with up protocol, LDL. time similar addition that looking So for existing a to on starting same

and to Phase eye had of be as added course, of over design, an likely design. And Phase little There both trial need disease because updated we data for a with data that months, unblinding. be proposing the II a to FDA then then we'll -- the that a of II be last because lock that stopped well. And to new of so gotten thyroid we've a and investigator share lot couple the trials,

list So priority top moment. that's at all the our of at the work right that's

Thomas Smith

clarifying Okay. other just Great. one question. Maybe

clarify, of You of really who I albumin the normal on good limit XXX and the any color some below provided XXX the lower XXX, just patients reduction at the albumin? fall guess received can you did seen dose regarding

Peter Salzmann

Right.

have sure, dose, the data, right individual well X. that quite the the provide of to useful such patient lower X.X, average it's average the, level than XXX normal the middle was I'm there number small the a in we the was above So but not in a

group XXX going going and changes going population, to have So confident that on that related issues a -- have to the when have we're manageable. are LDL be we albumin large is to as a they'll and to patients low not they're

right the the average that XXX-milligram see there. dose line with kind of on patients the do You

make albumin patients is already made I'll So dose in limited the during just then the a lower by is -- there -- who XXX pretty again, average the which I And reduction below XXX point in arm, It's the the group, presentation, obviously there's in large. the fell low. it there were was normal. that is difference but

the of the curve. the the being part have dose, So in part on on the of change in PK/PD about reduction and modelers a the flat albumin what whereas means as curve albumin that reduce you you is steep talk the big IgG

in So XXX reduce as very, favorable makes don't as very a the have you you much IgG dose, suppression. the And really dose. loss dose, this

XXX be And others. patient-to-patient for many some individuals, favorable some like because patients, will there's individual the for the the variability dose XXX and performs XXX people for

the changes that's of balance albumin nice a this minimal the I had patients, and and most provide X in options, dosage XXX set really lipids IgG slide different nice and together. here the for those suppression XXX, really those with a between on with options taking we of So doses, think will doses

Operator

Skorney questions line the next from Baird. of come Our with Brian

Brian Skorney

MG terms heavily aren't more see probably one unblinded in plans do maybe the Phase on been purely increase is you in your just study is you're treatment it patients a basis, interventional of And ensure of than on that and kind to Has III is really one starting to any thoughts provided how basically that being kind the expect LDL a about as My of or statins there arm purely management. study, conduct thinking the kind thought on at placebo? interventional? if would patients lipid of it question for baseline

Peter Salzmann

couple Yes. great there, Brian. questions really of A

dosing is are So a to and get with. people than going more modest first to of to relatively most have the management, low start some aren't of longer-term lipid of a all, of where in spot, those to first modest a a foremost, sweet regard background our to With approach and increase increases occur LDL on -- for going them in to

statin that something that be their but need statin the in a guidelines. rather everybody of that they discretion there going started start outside rough few some like or fall physician have may have the not we're of to at So might we guidelines, patients normal thinking for a to or we're

label the the in to events in guidelines. similarly that manage ultimately cholesterol other abnormality, have adverse through precaution the change to happen warning translate many regular regarding can increases physicians have a says products section, where that that a and lab recommendation And according note modest LDL those can

not change short-term the be in those using to and LDL a result may we In where albumin. studies, just may doses higher but

several professionals the have separate those medical versus including monitoring is unblinding, there do things physicians not We ensure do the or assessments. clinical who care that who having health in to place

things because even patient, can albumin important at standard in there. there's the some do albumin treatment of have physician the was So to We've that the a the done the but we prior involved understand be it was any can trials where unblinding, given in point.

blinded treatment going are don't to like an there's or that to we then short term, complexity. of level that So unblinding need states think And patients the might something that. in add during extra start period

terms So management. and statin generally, to more in of that's MG, regard with our thought

Operator

of with Capital. line Slutsky LifeSci Sam Our come questions next from the

Samuel Slutsky

a on first, guess ago. Brian's building question I second

So so in the increase or mg LDL dose. at XXX XX% the

help there's understand intervention? Just to as it this ] significance relates [ to no us an needing

Peter Salzmann

Right.

a down level So percentage lot more that's the the comes hopefully a great so It level. Sam. question, than to absolute

level, like XX% I population we're to population a prescriptive Brian, that broad-based sense that have versus large were a percentages the kind in, if were the at describing of we the where something magnitude XX% not going But get for a the anti-lipid XX%, And a that definitely low using of to are a we chronically was don't a to is regimen. you're think that if program. then and need as at as XX%, broad-based -- to So if it's chronic chronic, issue. important -- magnitude increase

randomized based about who patient. physicians XXX. that I few have here, that Thye'll looking who that at the is had I'm of the this-- they which patient the statin just decisions patients? look will individual an LDL statins, the in a So on make make there's absolute has XX. And see patients the you those of how slide middle now, at We primarily on if to are LDL a up can about you

didn't this with be had unlikely kind XX% of to and XX% on with or XX They're something. LDL the to doing change of or person up statin. XXX XXXX also their physicians If going gone a they background XX, therapy the anything. Now background from

like the of had optimized. who or you came the On management X%, in the hand, on patient lipid even their see before that XXX probably their statin on about other about an increased far they to milligrams, more increase right, a statin XXX, they baseline randomized was a of person, dose

So won't. the regardless variability there that's patients almost digits LDL, lower start XXXX the who going absolute looking in -- and need based in probably single the decision-making on higher intervention, have or when you're relatively who the may these are small of be more teens since at and increases people is to much

why to that's going not have trials. component be factor just one think a to and So large there's we anti-lipid our to more

Samuel Slutsky

Okay.

as kind differs to So well who I smaller then, guess need expected the it? of based I it indication that, with patients be guess is on by you might percentage have it data of

Peter Salzmann

our of next Right, obviously you population right. factors. difference in in autoimmune disease age the Yes, the business risk swath as doing there's some as prioritize broad And the we're of look in across what terms we is indications.

will few with there are younger are cardiac factors, little to patients them more a Some cardiac indication. of differences risk So be older indication factors, risk with some

Samuel Slutsky

time point by Okay. point start you And the saw this you see show and did up in the what all at kinetics level of increase, at then terms the this increases? this to lastly, on LDL differ of what time too, just

Peter Salzmann

in familiar this lower with that as XX and all reporting more gotten eye little the very data was X, percentages prospectively of data the going do the bit that it data have trial solid cholesterol XX And really are we've we was we ensure We're disease and the the -- there. that we're Yes. where saw a thyroid accurate. weeks you're today The to little measured at thin data bit from that of from most now. in comes the data and -- data

what did time mostly have first where weeks, And XX the had who some X points in we happened serum. and weeks was or look But intermediate some between patients so the stored apparent increase could X so. at we

rapid data, of -- went were off dropped and or over on So there. went But when trial, to or MG where week then a frame. open-label the they to they've then all in stable therapy we're based go similarly, LDL it's in to the similarly they time kind came weeks, every Sam. other going relatively up generally about X in small And

not bit triangulates well, data I'm it it's is different. pretty small because each a patient little but So showing just here

Operator

come questions Tsao next Our from line Douglas of Wainwright. with the H.C.

Douglas Tsao

your the to portion confirm you do of seeing, on just sort given study? don't anticipate magnitude to that effect the you so need Just is put just it of comments, -- you the patients expect a just trying have statins during blinded of

Peter Salzmann

Correct.

Douglas Tsao

physicians And a on terms patients in put sort therapy, to ] what in averse will the extension there management? to Or sort up of label statin sort in be -- that protocol? the terms prescribed of will -- be period, of [ ask of would be open to need left largely in of potentially

Peter Salzmann

the and other I some there'll population could factors. the on imagine trial of a little bit be and depending disease both,

to that physicians found of has are I they're with cholesterol know data whose cardiovascular one risk and some they very the to risk keep is things lower. to treated very or think what have the XXXX today data. when gone came interesting physicians bit that patients research of more are showed at who's very their a statin out and to up I we LDL I market interested of prescribe happens some want of to a anecdotal going with wanting that risk

different think management But that some to scientific that will will be create to some will sort treat also there'll and also predefined we other useful. that a us have sets create patients. we'll will designs a help will where of little type data probably leave which where allow answer their So and data we judgment, questions are understand be I of it bit to specific to how I physician prescriptive, think some trials clinicians

I'd we'll So with both time. imagine that end up over designs

I in extension long-term was about Doug. X there the examples, talking those And

Operator

call Pete are this time. no any hand questions to Salzmann to for the over There I closing further back comments. like at would

Peter Salzmann

Thanks for that.

So attention everybody's I appreciate and of a questions. just great lot really

We the given We a therapeutic have doses given looking have program, seen our extensive its where pretty modest the that we lot different and completed manageable as we're most be I LDL that for data of broad for a window. a should and of majority today, see. see trials lot review reviewed insight vast excited patients of be what patients. is by at And the from treated potential of will we signal at XXXX the

and to the indications look to all clinic plans those we've be learnings, that So in discussions of with into announcing based And get that's we'll to and the on get a got about excited hard we're working future back team done. I you our the forward more future.

Thanks, everyone.

Operator

you for participation. This your conclude Thank teleconference. does today's

great lines You may disconnect a at Have time. this your day.

Immunovant (IMVT) 1 Jun 212021 Q4 Earnings call transcript